IP Library Granted Patent US 10,626,170
Granted Patent B2
US 10,626,170 · App. 15/447,496 · Granted Apr 21, 2020

Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor

Inventor: Joshua Rabbani (New York, NY)
Assignee: Enzo Biochem, Inc.
C07K16/22C07K14/47C07K14/51C07K14/705C07K14/71C07K16/44C07K2317/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,626,170
App. No.
15/447,496
Granted
Apr 21, 2020
Kind
B2
Abstract

Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin. Further provided are compositions and peptides comprising a sulfonated epitope of sclerostin. Also provided by this invention are methods for production of such antibodies, both active and passive, and methods for identifying antibodies specific for sulfonation sites in Sclerostin and other antibodies which discriminate between sulfonated and unsulfonated forms of sclerostin. Physical and virtual screening processes are provided in this invention for identifying compounds which disrupt or inhibit sulfonation and the interaction between Sclerostin and binding partners. The antibodies and compositions of the present invention are useful in diagnostic and therapeutic applications directed to Sclerostin-related disorders.

Claims (14)

1. A method for production of a monoclonal antibody specific for a sulfonation site in Sclerostin, comprising the steps of:

immunizing an animal with a synthetic peptide derived from the Sclerostin amino acid sequence, wherein said peptide comprises a sulfonation site in said Sclerostin that comprises a tyrosine corresponding to Tyr43 or Tyr213 of human Sclerostin;

isolating antibody producing cells from said immunized animal;

fusing the isolated antibody producing cells with myeloma cells to form antibody producing hybridoma cells; and

screening the hybridoma cells to identify hybridoma cells that produce antibodies that discriminate between sulfonated and unsulfonated forms of said sulfonation site of Sclerostin.

2. The method of claim 1 , wherein said tyrosine is sulfonated in the synthetic peptide.

3. The method of claim 1 , wherein said tyrosine corresponds to Tyr43 of human Sclerostin.

4. The method of claim 3 , wherein said tyrosine is sulfonated in the synthetic peptide.

5. The method of claim 1 , wherein the synthetic peptide is selected from the group consisting of:

(a) ELGEYPEPPPELE (SEQ ID NO:8), wherein tyrosine is sulfonated;

(b) ELGEYPEPPPELE (SEQ ID NO:8), wherein tyrosine is not sulfonated;

(c) KANQAELENAY (SEQ ID NO:7), wherein tyrosine is sulfonated; and

(d) KANQAELENAY (SEQ ID NO:7), wherein tyrosine is not sulfonated.

6. The method of claim 5 , wherein the peptide is ELGEYPEPPPELE (SEQ ID NO:8), wherein tyrosine is sulfonated.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2018
From: RABBANI, JOSHUA
To: ENZO BIOCHEM, INC.
Reel/Frame 048147/0891 →
Continuity (2)
Division 12802447 · Jun 7, 2010
Related Publication 20170198033A1 · Jul 13, 2017